LAGUNA HILLS, Calif. / Oct 17, 2023 / Business Wire / Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced its first Root Canal Forum for General Dentists, an educational and networking experience created by clinicians, for clinicians aimed at increasing adoption of the GentleWave System. Taking place in Nashville from Oct. 20-21, this two-day forum is designed to support the advancement of endodontic treatment in the general practice by providing general dentists with the opportunity to gain insight into the use of the GentleWave System, learn from experienced peers and benefit from a hands-on, practical session and ‘Test Drive.’ The event will offer continuing education sessions led by nationally recognized instructors, as well as activities to promote peer-to-peer networking and connection with both endodontic specialists and general dentists.
At the forum, attendees will explore innovative avenues to elevate the overall patient experience, impact practice production and develop workflows for root canal therapy. Additionally, attendees will learn more about how technology can support consistency and predictability, review clinical case studies, apply learnings in a hands-on clinical lab with instructor oversight and more.
“With an ongoing commitment to empowering and partnering with general practitioners, we are thrilled to host our first-ever Root Canal Forum for General Dentists for current and prospective GentleWave System clinicians,” said Michael Smith, chief commercial officer at Sonendo. “We recognize the importance of peer-to-peer connection and discussion when it comes to the advancement of endodontic treatment, and we are proud to foster that with this event. Our goal is for attendees to walk away with new ideas regarding practice optimization and growth, patient care and other key topics. In addition to the attending general dentists, we are also grateful to our faculty, including several prominent endodontists, for their support.”
Renowned program instructors include Bruno Azevedo, DDS, MS, Sonia Chopra, DDS, MS, Alan Friedel, DDS, Derek Peek, DDS, MS, Scott Sayre, DDS, Sarah Sloan-Corrigan, BA, DAEF and Drew Smith, DDS.
Clinicians who have not yet tried the GentleWave Procedure will have the unique opportunity for a hands-on experience. For additional information on the Root Canal Forum, visit here.
For more information on the GentleWave System, visit https://gentlewave.com/doctor/.
About Sonendo
Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. Sonendo is also the parent company of TDO Software, the developer of widely used endodontic practice management software solutions, designed to simplify practice workflow. TDO Software integrates practice management, imaging, referral reporting and CBCT imaging, and offers built-in communication with the GentleWave System.
For more information on Sonendo, visit www.sonendo.com. For more information on the GentleWave System, visit www.gentlewave.com/doctor.
Last Trade: | US$2.47 |
Daily Change: | 2.24 973.91 |
Daily Volume: | 100 |
Market Cap: | US$1.030M |
November 08, 2023 September 28, 2023 August 09, 2023 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load